Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 1.9%

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) rose 1.9% during mid-day trading on Thursday . The stock traded as high as $1.12 and last traded at $1.08. Approximately 302,083 shares were traded during trading, a decline of 18% from the average daily volume of 369,111 shares. The stock had previously closed at $1.06.

Wall Street Analyst Weigh In

ONCY has been the subject of several research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Oncolytics Biotech in a research report on Friday, January 12th. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Oncolytics Biotech in a research report on Wednesday, February 14th. Finally, Raymond James started coverage on shares of Oncolytics Biotech in a report on Thursday, April 4th. They set an “outperform” rating and a $3.00 target price for the company.

Oncolytics Biotech Trading Up 0.9 %

The company’s fifty day moving average is $1.06 and its 200 day moving average is $1.28.

Oncolytics Biotech (NASDAQ:ONCY) last announced its earnings results on Thursday, March 7th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. Analysts forecast that Oncolytics Biotech Inc. will post -0.32 EPS for the current fiscal year.

Institutional Trading of Oncolytics Biotech

Large investors have recently added to or reduced their stakes in the company. Ausdal Financial Partners Inc. acquired a new stake in shares of Oncolytics Biotech during the 3rd quarter worth about $44,000. Advisor Resource Council bought a new position in Oncolytics Biotech during the fourth quarter worth about $135,000. Finally, International Assets Investment Management LLC increased its position in Oncolytics Biotech by 33.9% during the fourth quarter. International Assets Investment Management LLC now owns 269,699 shares of the company’s stock worth $364,000 after acquiring an additional 68,246 shares during the period. Institutional investors and hedge funds own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.